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Abstract
Background: Migraine is associated with an increased risk for cardiovascular disease (CVD). Both migraine and CVD are
highly heritable. However, the genetic liability for CVD among migraineurs is unclear.
Methods: We performed a genome-wide association study for incident CVD events during 12 years of follow-up among
5,122 migraineurs participating in the population-based Women’s Genome Health Study. Migraine was self-reported and
CVD events were confirmed after medical records review. We calculated odds ratios (OR) and 95% confidence intervals (CI)
and considered a genome-wide p-value ,5610
28 as significant.
Results: Among the 5,122 women with migraine 164 incident CVD events occurred during follow-up. No SNP was
associated with major CVD, ischemic stroke, myocardial infarction, or CVD death at the genome-wide level; however, five
SNPs showed association with p,5610
26. Among migraineurs with aura rs7698623 in MEPE (OR=6.37; 95% CI 3.15–12.90;
p=2.7610
27) and rs4975709 in IRX4 (OR=5.06; 95% CI 2.66–9.62; p=7.7610
27) appeared to be associated with ischemic
stroke, rs2143678 located close to MDF1 with major CVD (OR=3.05; 95% CI 1.98–4.69; p=4.3610
27), and the intergenic
rs1406961 with CVD death (OR=12.33; 95% CI 4.62–32.87; p=5.2610
27). Further, rs1047964 in BACE1 appeared to be
associated with CVD death among women with any migraine (OR=4.67; 95% CI 2.53–8.62; p=8.0610
27).
Conclusion: Our results provide some suggestion for an association of five SNPs with CVD events among women with
migraine; none of the results was genome-wide significant. Four associations appeared among migraineurs with aura, two
of those with ischemic stroke. Although our population is among the largest with migraine and incident CVD information,
these results must be treated with caution, given the limited number of CVD events among women with migraine and the
low minor allele frequencies for three of the SNPs. Our results await independent replication and should be considered
hypothesis generating for future research.
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Introduction
Migraine is a common and often disabling disorder affecting up
to 20% of the general population, women 3–4 times more often
than men [1]. Clinically migraine presents with recurrent
headache attacks and combinations of gastrointestinal and
autonomic nervous system symptoms [2], and up to one third of
patients experience transient focal neurological symptoms known
as migraine aura.
Migraine pathophysiology is incompletely understood. While
migraine is viewed as a primary disorder of the brain, vascular
mechanisms are also implicated. For example, endothelial
dysfunction and hypercoagulability [3] as well as altered vascular
reactivity [4] are found in migraine patients. In addition, the
current evidence on the association between migraine and
cardiovascular disease (CVD) was summarized in a recent meta-
analysis [5], which found a two-fold increased risk for ischemic
stroke among migraineurs, in particular those with migraine with
aura. Some individual studies suggest that the link between
migraine and CVD also extends to myocardial infarction (MI),
CVD death, and hemorrhagic stroke [6,7,8,9,10,11,12,13,14].
Family and twin studies have shown that genetic factors
importantly contribute to the pathophysiology of both migraine
and CVD. In addition, with respect to the established association
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22106between migraine and CVD, the influence of gene variants has
recently been investigated, showing for example a modulatory
effect of the MTHFR 677C.T [15] and ACE D/I [16]
polymorphisms among women.
Given the unique physiology among migraineurs, specifically
migraineurs with aura, which suggests the potential for a genetic
risk of CVD, we sought to investigate the genetic liability for CVD
among migraineurs. Such a design eliminates a potential
confounding effect of migraine on the association between genetic
markers and CVD. This contrasts with a study design comparing
migraineurs to non-migraineurs, which would also investigate an
interaction between the phenotype migraine and genetic markers
on CVD risk.
Hence, we performed a genome-wide association study (GWAS)
among women with migraine comparing those who developed a
CVD event to those who did not.
Methods
Study population
The Women’s Health Study (WHS) and its subpopulation with
genome-wide genetic data, the Women’s Genome Health Study
(WGHS), form the base populations for this study, which was
approved by the Institutional Review Board of Brigham and
Women’s Hospital. The WHS was a randomized trial designed to
test the benefits and risks of low-dose aspirin and vitamin E in the
primary prevention of CVD and cancer [17,18], in which 39,876
U.S. female health professionals aged $45 years and free of major
illnesses were enrolled. WHS participants provided extensive
information about health and lifestyle at baseline and during
ongoing follow-up. Prior to randomization, blood samples were
collected from 28,345 participating women, who provided consent
for blood based analysis [19]. These women formed the source
population for the WGHS.
Ascertainment of migraine
Participants in WHS were asked on the baseline questionnaire:
‘‘Have you ever had migraine headaches?’’ and ‘‘In the past year,
have you had migraine headaches?’’ From this information,
women were categorized as ‘‘any history of migraine;’’ ‘‘active
migraine’’ (self-reported migraine during the past year); and ‘‘prior
migraine’’ (report of ever having had a migraine but none in the
year prior to completing the questionnaire). This classification and
self-reported migraine have shown good agreement with current
International Headache Society (IHS) criteria for migraine [8,20].
Participants reporting ‘‘active migraine’’ were further asked about
specific migraine features, including aura. Responses to the
question whether they had an ‘‘aura or any indication a migraine
is coming,’’ were used to classify women into active migraine with
and without aura. Furthermore, on each of the follow-up
questionnaires participants were asked about new occurrences of
migraine (‘‘incident migraine’’). From this information, we defined
two main categories: 1) no migraine (never reported migraine
throughout the study), and 2) any migraine (any indication of
migraine throughout the study). For additional analyses we also
looked at specific migraine features, including migraine aura
status, among those reporting ‘‘active migraine’’ at baseline.
Ascertainment of CVD
During follow-up, women participating in the WHS self-
reported cardiovascular events. Medical records were obtained
for all events and reviewed by an Endpoints Committee of
physicians. Nonfatal stroke was confirmed if the participant had a
new focal neurological deficit of sudden or rapid onset that
persisted for .24 hours. Major stroke subtype classification
(ischemic, hemorrhagic, or unknown) was based on available
clinical and diagnostic information with excellent interrater
agreement [21]. The occurrence of MI was confirmed if symptoms
met World Health Organization criteria and if the event was
associated with abnormal levels of cardiac enzymes or abnormal
electrocardiograms. Cardiovascular deaths were confirmed by
review of autopsy reports, death certificates, medical records, or
information obtained from next of kin or family members. We
evaluated incident major CVD, a combined endpoint defined as
the first of any of these events: nonfatal ischemic stroke, nonfatal
MI, or death from ischemic CVD. We also evaluated any first
ischemic stroke, any first MI and CVD deaths separately.
Genotyping
Genotyping in WGHS was performed using the Human-
Hap300 Duo ‘‘+’’ chips or the combination of the HumanHap300
Duo and iSelect chips (Illumina, San Diego, CA) with the Infinium
II protocol and has been described elsewhere [19]. Among
individuals with successful genome-wide genotyping, 23,294 were
identified as having self-reported European ancestry that could be
verified on the basis of multidimensional scaling analysis of identity
by state using 1443 ancestry informative markers in PLINK v.
1.07 [22]. In the final dataset there were a total of 339,596 SNPs
with a minor allele frequency (MAF) .1%, successful genotyping
in .90% of subjects, and deviations from Hardy-Weinberg
equilibrium not exceeding P=10
26 in significance.
Statistical analysis
Age-adjusted logistic regression in PLINK [22] was used to
investigate the association between gene variants and CVD events
in the WGHS cohort and odds ratios (OR) and 95% confidence
intervals (CI) were calculated. In the genome-wide analyses, we
assumed an additive relationship between the number of copies of
the minor allele of each SNP and the age-adjusted log-odds of
CVD events. We considered a threshold of p,5610
28 for
genome-wide significance [23]. For sensitivity analysis, we also
examined two multivariable-adjusted logistic models for the SNPs
implicated in the age-adjusted models. In multivariable-adjusted
model 1 we considered the following covariates: age (continuous),
history of hypertension (yes, no), low-density lipoprotein (LDL)
cholesterol (continuous), high-density lipoprotein (HDL) choles-
terol (continuous), menopausal status (yes, no), smoking (never,
past, current), and family history of myocardial infarction before
age 60 (yes, no). Multivariable-adjusted model 2 was adjusted for
the same covariates as model 1 plus the top 10 eigenvectors for
sub-European population structure.
We evaluated the associations between SNPs and CVD events
among all migraineurs as well as among women with migraine
with aura and migraine without aura separately. We further
investigated whether the association of previously reported genetic
markers for MI [24], ischemic stroke [25,26], and silent brain
infarcts [27] with any of the CVD events is modified by migraine
aura status by adding an interaction term between the marker and
aura status (yes, no) (SNP*aura) to the logistic models. For
candidate gene analysis, SNPs within 25 kb of the transcribed
region of each gene were considered (Table S1). To estimate the
statistical significance of the most strongly associated SNP within
the locus accounting for multiple hypothesis testing, we computed
a locus-wide effective number of SNPs based on LD relationships
in the WGHS and used this number in the S ˇida ´k p-value
adjustment procedure as described [28].
Additional programming was performed in R. All annotations
derive from human genome reference sequence hg18 (NCBI build
Genetic Determinants of CVD Events in Migraine
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database (build 129) as represented by the UCSC database.
Results
Of the 23,294 women with verified European ancestry, 5122
reported any migraine during the study, 4247 at baseline and 875
during follow-up. Among the women with migraine information
from baseline, 3003 reported active migraine and 1244 prior
migraine. Further, among women with active migraine 1177
(39.2%) had migraine with aura and 1826 (60.8%) migraine
without aura. Information on incident migraine did not allow
further classification according to migraine aura status.
Among the 5122 women with any migraine 164 developed a
major CVD event during follow-up (73 MIs, 68 ischemic strokes,
35 CVD deaths). The respective numbers of CVD cases for
migraine with aura and migraine without aura are: migraine with
aura (1177 women)—55 major CVDs, 26 MIs, 21 ischemic
strokes, 12 CVD deaths; migraine without aura (1826 women)—
38 major CVDs, 18 MIs, 17 ischemic strokes, 7 CVD deaths.
Baseline characteristics of the participating women according to
major CVD are summarized in Table 1. Women with migraine
experiencing major CVD during the study were older, were more
likely to have a history of hypertension, and had higher systolic
and diastolic blood pressure compared to migraineurs without
major CVD. Women with major CVD also had higher LDL and
lower HDL cholesterol levels, were more likely to be postmeno-
pausal, and to be current smokers.
In the genome-wide analysis no SNP reached the conventional
significance threshold of p,5610
28 in age-adjusted logistic
models assuming an additive relationship between the minor
allele dose and log-odds of major CVD, ischemic stroke, MI or
CVD death. Nevertheless, investigation of the quantile-quantile
plots of probability values for the association between SNPs and
CVD events among migraineurs indicated a slight excess of small
p-values for some of the associations after controlling for modest
inflation of the test statistic (lGC=1.03, Figure 1). We thus
decided to further investigate SNPs suggestive of an association
with p-values ,5610
26.
Five SNPs on different chromosomes showed associations
with CVD events among women with migraine at the
p,5610
26 threshold suggesting increased risks for carriers of
the minor alleles (Table 2). Four of the associations were seen
among women with migraine with aura: two SNPs suggested
an increased risk for ischemic stroke (rs7698623 [Figure S1],
odds ratio [OR]=6.37, 95% confidence interval [CI] 3.15–
12.90, p=2.7610
27; rs4975709 [Figure S2], OR=5.06, 95%
CI 2.66–9.62, p=7.7610
27), one for major CVD (rs2143678
[Figure S3], OR=3.05, 95% CI 1.98–4.69, p=4.3610
27),
and one for CVD death (rs1406961 [Figure S4], OR=12.33,
95% CI 4.62–32.87, p=5.2610
27). Further, one SNP
suggested an increased risk for CVD death among women
with any migraine (rs1047964 [Figure S5], OR=4.67, 95%
CI 2.53–8.62, p=8.0610
27). All ORs are large compared with
effect estimates for CVD from studies in populations not
selected for migraine, which for example report of a doubling
of the relative risk for ischemic stroke among migraineurs,
particularly migraineurs with au r a[ 5 ] .F u r t h e r ,o u ro b s e r v e d
ORs need to be interpreted in terms of the rather low minor
allele frequencies (MAF) for some of the SNPs (Table 2).
The significance and magnitude of the associations were
very similar in the multivariable-adjusted additive models
(Table 2).
In addition to our model comparing migraineurs with CVD to
migraineurs without CVD, we also explored a model comparing
migraineurs with CVD to controls free of migraine and CVD
(n=17,247). The top hits were the same for the associations
between migraine with aura and ischemic stroke, migraine with
aura and major CVD, and any migraine and CVD death (data not
shown). For the association between migraine with aura and CVD
death the SNP on chromosome 20 (rs1406961) was only the
second most significant one, while rs1047964 (see previous
paragraph) was the top SNP.
Additional analyses did not indicate that the association
between SNPs in genes previously identified as markers for MI,
ischemic stroke, and silent brain infarcts (Table S1) and any of
the CVD events is modified by migraine aura status (data not
shown).
Table 1. Baseline characteristics of migraineurs according to cardiovascular disease status (n=5,122).
Migraineurs without
cardiovascular events (n=4,958)
Migraineurs with cardiovascular
events (n=164) p-value*
Age, y (SD) 53.3 (6.3) 58.9 (8.3) 9.6610
215
History of hypertension, % 23.5 48.2 8.5610
213
Systolic blood pressure, mmHg (SD) 122.9 (13.2) 131.1 (15.0) 8.6610
211
Diastolic blood pressure, mmHg (SD) 76.9 (9.2) 79.6 (9.4) 3.0610
24
LDL cholesterol, mg/dl (SD) 123.3 (35.1) 129.4 (34.6) 2.5610
22
HDL cholesterol, mg/dl (SD) 53.1 (15.2) 49.3 (16.3) 3.8610
23
Postmenopausal status, % 49.0 67.1 7.5610
26
Smoking, %
Current 10.6 23.2
Past 37.1 26.2
Never 52.4 50.6 7.4610
27
Family history of myocardial infarction before age 60, % 13.9 16.7 0.41
Numbers are means (SD), unless otherwise stated.
*P-value from t-test for continuous data and chi-square test for categorical data.
doi:10.1371/journal.pone.0022106.t001
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The results of this GWAS do not indicate that any of the
339,596 SNPs are associated with CVD events among migraineurs
at the genome-wide level. After lowering the significance threshold
to 5610
26 there was some suggestion that five SNPs at different
loci might be implicated. Two of the SNPs suggested an
association with ischemic stroke (rs7698623, rs4975709), one with
major CVD (rs2143678), and one with CVD death (rs1406961)
among women with migraine with aura. In addition, rs1047964
appeared to be associated with CVD death among women with
any migraine. There is no indication that migraine aura status
modifies the association between previously described markers for
MI, ischemic stroke, and silent brain infarcts with any of the CVD
events. Although the WGHS population is among the largest with
information about both migraine and incident CVD, our results
need to be treated with caution, since the number of CVD events
was only modest and the MAFs for three of the SNPs was low.
Migraine, in particular migraine with aura, has been associated
with CVD. The evidence was summarized in a recent meta-
analysis indicating a two-fold increased risk for ischemic stroke,
which only appears for migraine with aura [5]. The evidence is less
clear for other CVD events; however, individual studies suggest
that this pattern may also extend to MI, CVD death, and
hemorrhagic stroke [6,7,8,9,10,11,12,13,14]. The association
between migraine and ischemic vascular events was independent
of many CVD risk factors in many studies [7,8]. Furthermore, the
increased risk of ischemic stroke is more apparent among
migraineurs without CVD risk factors [29,30,31]. In addition
functional [4], cellular [32], and genetic data [33] indicate shared
biological vulnerability between vascular disorders and migraine.
Investigating the genetic liability for CVD among migraineurs
has only recently begun. Two analyses reported on the influence of
single gene variants on the migraine-CVD association and showed
a modulatory effect of the MTHFR 677C.T [15] and ACE D/I
[16] polymorphisms among women. The two-fold increased risk of
Figure 1. Quantile-quantile plots for the association between SNPs and CVD among women with migraine.
doi:10.1371/journal.pone.0022106.g001
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those migraineurs with aura also carrying the MTHFR 677TT
genotype. This was only seen for ischemic stroke and not for MI.
With regard to the ACE D/I polymorphism, only migraineurs with
aura carrying the DD/DI genotype seemed to be at increased risk
for ischemic stroke and MI, but not carriers of the II genotype.
The approach of our study is novel in two different ways. First,
we compared migraineurs with CVD events to migraineurs
without CVD events in contrast to previous studies comparing
migraineurs to non-migraineurs. This design eliminates a potential
confounding effect of migraine with gene variants on CVD events
and specifically addresses the question which gene variants are
associated with CVD events among migraineurs. Second, our
study investigates the effect of genetic markers among migraineurs
on their risk for CVD events from a genome-wide perspective.
None of the investigated SNPs was significantly associated with
CVD events among migraineurs at a genome-wide level.
However, our analyses provide some indication of an association
of five genetic variants with CVD events at a suggestive
significance threshold. In addition, our results—similar to previous
non-genetic studies—support the concept that the risk for CVD
among migraineurs is not strongly confounded by classical CVD
risk factors. First, results from the multivariable-adjusted models
are very similar to age-adjusted models (Table 2), although CVD
risk factors are more prevalent among migraineurs with CVD
events than among those without CVD events (Table 1). This is
likely due to a co-linearity between age and classical CVD risk
factors. Second, none of the five implicated genetic variants has
previously been reported to be associated with CVD risk factors or
CVD events.
The potential function for the five variants with regard to an
increased CVD risk among migraineurs is unclear. A summary of
the known functional characteristics of these variants is presented
in Table 3. However, it is important to note, that four of the SNPs
were identified for the association between migraine with aura and
CVD events and two of those specifically for the association with
ischemic stroke. This agrees with data from observational studies
suggesting a particularly strong link between migraine with aura
and ischemic stroke [5].
Our study has several strengths, including CVD events being
verified by an endpoints committee of physicians, detailed
information on many potential CVD risk factors, and genetic
information from 339,596 SNPs covering the whole genome. In
addition, the homogenous nature of the cohort, consisting only of
white women aged $45 years, may reduce confounding. For
example, while there is no reason to assume that migraine
pathophysiology is different between women and men, the
phenotypic expression among migraineurs may differ by gender
and age. This is suggested, for example, by data showing that the
migraine-ischemic stroke association is greater among younger
women than older women [5], which may depend on a changing
pattern in cardiovascular risk profile [30].
However, several limitations should be considered. First, and
most importantly, data to directly replicate our results are not
available to verify our results or perform a meta-analysis.
However, we believe that this should not hold back research,
since our results may stimulate new research ideas and accelerate
ongoing research. Second, we cannot exclude the possibility of
spurious associations. The number of women with migraine
experiencing a CVD event was limited (n=164) and the odds
ratios for the five SNPs are rather large with effect sizes between 3
and 12 compared to usually much smaller odds ratios found in
association studies for complex and heterogeneous disorder. For
rs7698623, rs1047964, and rs1406961 this may also in part be due
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interpreted with caution. Third, migraine and aura status were
self-reported and were not classified according to strict IHS
criteria [2]. Although previous reports from the WHS have shown
good agreement of our classification with modified IHS criteria
from 1988 [8], and despite excellent agreement between self-
reported migraine and migraine classification based on IHS
criteria from 2004 in the WHS [20], non-differential misclassifi-
cation is possible, which may in part explain some of our null
findings. However, the prevalence of migraine (18.3%) and
migraine aura (39.5% of migraineurs) is similar to those reported
in other population-based studies [34,35]. Finally, we only
considered an additive genetic model of transmission. However,
the vast majority of gene-phenotype associations follow an additive
model, which would also have sufficient power to capture
dominant modes of transmission. While recessive modes of
transmission may be missed, we consider this a minor disadvan-
tage because they are rare and mostly relevant for monogenic
disorders.
Our results demand additional epidemiological studies and
basic science research and should be considered hypothesis
generating at present. First, large well-defined cohorts are needed
with standardized information on migraine and aura status,
gender, ethnicity, CVD risk factors, and other medical as well as
genetic information, to verify the potential role of the gene variants
for the CVD risk among migraineurs. In addition, further insight
into the biological function of these genes may advance the
understanding of the migraine-CVD link.
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